TG Therapeutics, Inc. (TGTX)
54.17
+1.01
(+1.90%)
USD |
NASDAQ |
Oct 23, 16:00
54.35
+0.18
(+0.33%)
Pre-Market: 20:00
TG Therapeutics Price to Book Value : 13.73 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 13.73 |
| October 22, 2026 | 13.47 |
| October 21, 2026 | 13.48 |
| October 20, 2026 | 13.82 |
| October 19, 2026 | 13.51 |
| October 16, 2026 | 13.68 |
| October 15, 2026 | 14.19 |
| October 14, 2026 | 13.78 |
| October 13, 2026 | 13.77 |
| October 12, 2026 | 14.01 |
| October 09, 2026 | 14.03 |
| October 08, 2026 | 13.52 |
| October 07, 2026 | 13.42 |
| October 06, 2026 | 13.23 |
| October 05, 2026 | 13.66 |
| October 02, 2026 | 13.76 |
| October 01, 2026 | 13.59 |
| September 30, 2026 | 14.13 |
| September 29, 2026 | 14.24 |
| September 28, 2026 | 14.24 |
| September 25, 2026 | 14.55 |
| September 24, 2026 | 14.58 |
| September 23, 2026 | 14.19 |
| September 22, 2026 | 14.73 |
| September 21, 2026 | 14.48 |
| Date | Value |
|---|---|
| September 18, 2026 | 14.41 |
| September 17, 2026 | 14.31 |
| September 16, 2026 | 14.15 |
| September 15, 2026 | 13.44 |
| September 14, 2026 | 13.68 |
| September 11, 2026 | 13.66 |
| September 10, 2026 | 14.04 |
| September 09, 2026 | 13.85 |
| September 08, 2026 | 14.12 |
| September 04, 2026 | 14.19 |
| September 03, 2026 | 14.37 |
| September 02, 2026 | 14.42 |
| September 01, 2026 | 14.21 |
| August 31, 2026 | 13.76 |
| August 28, 2026 | 13.67 |
| August 27, 2026 | 14.12 |
| August 26, 2026 | 13.94 |
| August 25, 2026 | 14.04 |
| August 24, 2026 | 14.19 |
| August 21, 2026 | 13.75 |
| August 20, 2026 | 12.81 |
| August 19, 2026 | 13.10 |
| August 18, 2026 | 12.74 |
| August 17, 2026 | 12.49 |
| August 14, 2026 | 12.35 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Krystal Biotech, Inc. | 6.783 |
| Vertex Pharmaceuticals, Inc. | 6.556 |
| SELLAS Life Sciences Group, Inc. | 16.93 |
| Travere Therapeutics, Inc. | 192.33 |
| Alnylam Pharmaceuticals, Inc. | 22.13 |
Price to Book Value Related Metrics
| PE Ratio | 19.73 |
| PS Ratio | 10.80 |
| PEG Ratio | 0.0311 |
| Price to Free Cash Flow | 496.76 |
| Price | 54.17 |
| Earnings Yield | 5.07% |
| Market Cap | 8.292B |
| PEGY Ratio | 0.0311 |
| Operating PE Ratio | 63.35 |
| Normalized PE Ratio | 19.36 |